Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Schema
  9. External Links
  10. Analytics And Tracking
  11. Libraries
  12. CDN Services

We are analyzing https://link.springer.com/article/10.1007/s10495-007-0120-6.

Title:
Involvement of c-Jun NH2-terminal kinase and nitric oxide-mediated mitochondria-dependent intrinsic pathway signaling in cardiotoxin-induced muscle cell death: role of testosterone | Apoptosis
Description:
To test the hypothesis that c-Jun NH2-terminal kinase (JNK) and nitric oxide (NO)-mediated signaling plays an important role in muscle cell apoptosis, we examined the contribution of these molecules in muscle cell apoptosis during cardiotoxin (ctx)-induced muscle injury in mice. Compared to controls, where no apoptosis was detected, the percent of muscle cell apoptosis rose significantly (P < 0.05) at 4 h (27%) after ctx-treatment and increased further progressively up to 16 h posttreatment (80%), before it fell again at 24 h posttreatment (38%). Initiation of apoptosis was preceded by JNK activation and elevated levels of B-cell lymphoma-2 (BCL-2) in the mitochondrial fractions (BAX levels remained unaffected). Ctx treatment also resulted in the inactivation of BCL-2 through phosphorylation at serine 70, thereby perturbing the BAX/BCL-2 rheostat, and the subsequent activation of the cytochrome c-mediated death pathway. Concomitant administration of SP600125, a selective JNK inhibitor, or aminoguanidine (AG), a selected inducible nitric oxide synthase (iNOS) inhibitor, effectively diminished BCL-2 phosphorylation, suppressed cytochrome c release from mitochondria and caspase activation, and significantly prevented ctx-induced muscle cell apoptosis. In additional studies, we examined the role of testosterone in preventing such ctx-induced muscle cell apoptosis. Collectively, the present study emphasizes the role of a new signal transduction pathway involving JNK and iNOS that promotes ctx-induced myocyte apoptosis by provoking BCL-2 phosphorylation, leading to its inactivation, and subsequent activation of the intrinsic pathway signaling. Testosterone therapy has no protective effect in acute muscle injury associated with increased muscle cell death after ctx-treatment.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

  • Education
  • Health & Fitness
  • Fitness & Wellness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 7,626,182 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure how the site profits.

Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Link.springer.com might be cashing in, but we can't detect the method they're using.

Keywords {🔍}

google, scholar, article, cas, pubmed, apoptosis, muscle, cell, kinase, bcl, jnk, cells, nitric, role, protein, wang, signaling, death, sinhahikim, sinha, hikim, oxide, activation, pathway, testosterone, phosphorylation, lee, biol, cjun, inducible, synthase, skeletal, physiol, mitogenactivated, rat, endocrinol, usa, shen, access, apoptotic, androgen, cancer, human, metab, privacy, cookies, content, research, nhterminal, inhibitor,

Topics {✒️}

c-jun nh2-terminal kinase ccaat/enhancer-binding protein-beta jun n-terminal kinase mitogen-activated protein kinases b-cell lymphoma-2 month download article/chapter inducible nitric-oxide synthase nitric oxide-induced apoptosis estradiol-stimulated cell proliferation intrinsic pathway signaling article sinha-hikim diallyl trisulphide-induced apoptosis sinha hikim ap raf-1/mek/erk cascade harbor-ucla medical center p38 map kinase p38 protein kinases indrani sinha-hikim induced muscle injury lymphoid tumor cells prostate cancer cells mediated signaling plays nitric oxide signaling drug-induced bcl-2 phosphorylation human skeletal muscle erk/jnk map kinases activating transcription factor-2 2-methoxyestradiol-induced p53 induction acute muscle injury nuclear factor kappa full article pdf muscle cell apoptosis article apoptosis aims nitric oxide synthases hind limb suspension androgen induced acceleration muscle fiber hypertrophy key apoptotic pathways privacy choices/manage cookies apoptotic signal transduction vinblastine-induced phosphorylation muscle fiber apoptosis bcl-2 related proteins stretch-induced apoptosis lps-induced hyperglycemia satellite cell number related subjects human primary neurons hypoxia sensitizes cells ovarian carcinoma cells

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Involvement of c-Jun NH2-terminal kinase and nitric oxide-mediated mitochondria-dependent intrinsic pathway signaling in cardiotoxin-induced muscle cell death: role of testosterone
         description:To test the hypothesis that c-Jun NH2-terminal kinase (JNK) and nitric oxide (NO)-mediated signaling plays an important role in muscle cell apoptosis, we examined the contribution of these molecules in muscle cell apoptosis during cardiotoxin (ctx)-induced muscle injury in mice. Compared to controls, where no apoptosis was detected, the percent of muscle cell apoptosis rose significantly (P < 0.05) at 4 h (27%) after ctx-treatment and increased further progressively up to 16 h posttreatment (80%), before it fell again at 24 h posttreatment (38%). Initiation of apoptosis was preceded by JNK activation and elevated levels of B-cell lymphoma-2 (BCL-2) in the mitochondrial fractions (BAX levels remained unaffected). Ctx treatment also resulted in the inactivation of BCL-2 through phosphorylation at serine 70, thereby perturbing the BAX/BCL-2 rheostat, and the subsequent activation of the cytochrome c-mediated death pathway. Concomitant administration of SP600125, a selective JNK inhibitor, or aminoguanidine (AG), a selected inducible nitric oxide synthase (iNOS) inhibitor, effectively diminished BCL-2 phosphorylation, suppressed cytochrome c release from mitochondria and caspase activation, and significantly prevented ctx-induced muscle cell apoptosis. In additional studies, we examined the role of testosterone in preventing such ctx-induced muscle cell apoptosis. Collectively, the present study emphasizes the role of a new signal transduction pathway involving JNK and iNOS that promotes ctx-induced myocyte apoptosis by provoking BCL-2 phosphorylation, leading to its inactivation, and subsequent activation of the intrinsic pathway signaling. Testosterone therapy has no protective effect in acute muscle injury associated with increased muscle cell death after ctx-treatment.
         datePublished:2007-09-05T00:00:00Z
         dateModified:2007-09-05T00:00:00Z
         pageStart:1965
         pageEnd:1978
         sameAs:https://doi.org/10.1007/s10495-007-0120-6
         keywords:
            JNK
            iNOS
            BCL-2 phosphorylation
            Myocyte apoptosis
            Muscle injury
            Cancer Research
            Cell Biology
            Oncology
            Biochemistry
            general
            Virology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10495-007-0120-6/MediaObjects/10495_2007_120_Fig1_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10495-007-0120-6/MediaObjects/10495_2007_120_Fig2_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10495-007-0120-6/MediaObjects/10495_2007_120_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10495-007-0120-6/MediaObjects/10495_2007_120_Fig4_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10495-007-0120-6/MediaObjects/10495_2007_120_Fig5_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10495-007-0120-6/MediaObjects/10495_2007_120_Fig6_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10495-007-0120-6/MediaObjects/10495_2007_120_Fig7_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10495-007-0120-6/MediaObjects/10495_2007_120_Fig8_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10495-007-0120-6/MediaObjects/10495_2007_120_Fig9_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10495-007-0120-6/MediaObjects/10495_2007_120_Fig10_HTML.gif
         isPartOf:
            name:Apoptosis
            issn:
               1573-675X
               1360-8185
            volumeNumber:12
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Indrani Sinha-Hikim
               affiliation:
                     name:Charles R. Drew University
                     address:
                        name:Division of Endocrinology, Metabolism, and Molecular Medicine (I.S.-H;M.B; RS), Charles R. Drew University, Los Angeles, USA
                        type:PostalAddress
                     type:Organization
                     name:David Geffen School of Medicine at UCLA and Los Angeles Biomedical Research Institute
                     address:
                        name:Division of Endocrinology (A.P.S.H.), Harbor-UCLA Medical Center, David Geffen School of Medicine at UCLA and Los Angeles Biomedical Research Institute, Torrance, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Mellisa Braga
               affiliation:
                     name:Charles R. Drew University
                     address:
                        name:Division of Endocrinology, Metabolism, and Molecular Medicine (I.S.-H;M.B; RS), Charles R. Drew University, Los Angeles, USA
                        type:PostalAddress
                     type:Organization
                     name:David Geffen School of Medicine at UCLA and Los Angeles Biomedical Research Institute
                     address:
                        name:Division of Endocrinology (A.P.S.H.), Harbor-UCLA Medical Center, David Geffen School of Medicine at UCLA and Los Angeles Biomedical Research Institute, Torrance, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ruoqing Shen
               affiliation:
                     name:Charles R. Drew University
                     address:
                        name:Division of Endocrinology, Metabolism, and Molecular Medicine (I.S.-H;M.B; RS), Charles R. Drew University, Los Angeles, USA
                        type:PostalAddress
                     type:Organization
                     name:David Geffen School of Medicine at UCLA and Los Angeles Biomedical Research Institute
                     address:
                        name:Division of Endocrinology (A.P.S.H.), Harbor-UCLA Medical Center, David Geffen School of Medicine at UCLA and Los Angeles Biomedical Research Institute, Torrance, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Amiya P. Sinha Hikim
               affiliation:
                     name:Charles R. Drew University
                     address:
                        name:Division of Endocrinology, Metabolism, and Molecular Medicine (I.S.-H;M.B; RS), Charles R. Drew University, Los Angeles, USA
                        type:PostalAddress
                     type:Organization
                     name:David Geffen School of Medicine at UCLA and Los Angeles Biomedical Research Institute
                     address:
                        name:Division of Endocrinology (A.P.S.H.), Harbor-UCLA Medical Center, David Geffen School of Medicine at UCLA and Los Angeles Biomedical Research Institute, Torrance, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Involvement of c-Jun NH2-terminal kinase and nitric oxide-mediated mitochondria-dependent intrinsic pathway signaling in cardiotoxin-induced muscle cell death: role of testosterone
      description:To test the hypothesis that c-Jun NH2-terminal kinase (JNK) and nitric oxide (NO)-mediated signaling plays an important role in muscle cell apoptosis, we examined the contribution of these molecules in muscle cell apoptosis during cardiotoxin (ctx)-induced muscle injury in mice. Compared to controls, where no apoptosis was detected, the percent of muscle cell apoptosis rose significantly (P < 0.05) at 4 h (27%) after ctx-treatment and increased further progressively up to 16 h posttreatment (80%), before it fell again at 24 h posttreatment (38%). Initiation of apoptosis was preceded by JNK activation and elevated levels of B-cell lymphoma-2 (BCL-2) in the mitochondrial fractions (BAX levels remained unaffected). Ctx treatment also resulted in the inactivation of BCL-2 through phosphorylation at serine 70, thereby perturbing the BAX/BCL-2 rheostat, and the subsequent activation of the cytochrome c-mediated death pathway. Concomitant administration of SP600125, a selective JNK inhibitor, or aminoguanidine (AG), a selected inducible nitric oxide synthase (iNOS) inhibitor, effectively diminished BCL-2 phosphorylation, suppressed cytochrome c release from mitochondria and caspase activation, and significantly prevented ctx-induced muscle cell apoptosis. In additional studies, we examined the role of testosterone in preventing such ctx-induced muscle cell apoptosis. Collectively, the present study emphasizes the role of a new signal transduction pathway involving JNK and iNOS that promotes ctx-induced myocyte apoptosis by provoking BCL-2 phosphorylation, leading to its inactivation, and subsequent activation of the intrinsic pathway signaling. Testosterone therapy has no protective effect in acute muscle injury associated with increased muscle cell death after ctx-treatment.
      datePublished:2007-09-05T00:00:00Z
      dateModified:2007-09-05T00:00:00Z
      pageStart:1965
      pageEnd:1978
      sameAs:https://doi.org/10.1007/s10495-007-0120-6
      keywords:
         JNK
         iNOS
         BCL-2 phosphorylation
         Myocyte apoptosis
         Muscle injury
         Cancer Research
         Cell Biology
         Oncology
         Biochemistry
         general
         Virology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10495-007-0120-6/MediaObjects/10495_2007_120_Fig1_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10495-007-0120-6/MediaObjects/10495_2007_120_Fig2_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10495-007-0120-6/MediaObjects/10495_2007_120_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10495-007-0120-6/MediaObjects/10495_2007_120_Fig4_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10495-007-0120-6/MediaObjects/10495_2007_120_Fig5_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10495-007-0120-6/MediaObjects/10495_2007_120_Fig6_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10495-007-0120-6/MediaObjects/10495_2007_120_Fig7_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10495-007-0120-6/MediaObjects/10495_2007_120_Fig8_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10495-007-0120-6/MediaObjects/10495_2007_120_Fig9_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10495-007-0120-6/MediaObjects/10495_2007_120_Fig10_HTML.gif
      isPartOf:
         name:Apoptosis
         issn:
            1573-675X
            1360-8185
         volumeNumber:12
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Indrani Sinha-Hikim
            affiliation:
                  name:Charles R. Drew University
                  address:
                     name:Division of Endocrinology, Metabolism, and Molecular Medicine (I.S.-H;M.B; RS), Charles R. Drew University, Los Angeles, USA
                     type:PostalAddress
                  type:Organization
                  name:David Geffen School of Medicine at UCLA and Los Angeles Biomedical Research Institute
                  address:
                     name:Division of Endocrinology (A.P.S.H.), Harbor-UCLA Medical Center, David Geffen School of Medicine at UCLA and Los Angeles Biomedical Research Institute, Torrance, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Mellisa Braga
            affiliation:
                  name:Charles R. Drew University
                  address:
                     name:Division of Endocrinology, Metabolism, and Molecular Medicine (I.S.-H;M.B; RS), Charles R. Drew University, Los Angeles, USA
                     type:PostalAddress
                  type:Organization
                  name:David Geffen School of Medicine at UCLA and Los Angeles Biomedical Research Institute
                  address:
                     name:Division of Endocrinology (A.P.S.H.), Harbor-UCLA Medical Center, David Geffen School of Medicine at UCLA and Los Angeles Biomedical Research Institute, Torrance, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ruoqing Shen
            affiliation:
                  name:Charles R. Drew University
                  address:
                     name:Division of Endocrinology, Metabolism, and Molecular Medicine (I.S.-H;M.B; RS), Charles R. Drew University, Los Angeles, USA
                     type:PostalAddress
                  type:Organization
                  name:David Geffen School of Medicine at UCLA and Los Angeles Biomedical Research Institute
                  address:
                     name:Division of Endocrinology (A.P.S.H.), Harbor-UCLA Medical Center, David Geffen School of Medicine at UCLA and Los Angeles Biomedical Research Institute, Torrance, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Amiya P. Sinha Hikim
            affiliation:
                  name:Charles R. Drew University
                  address:
                     name:Division of Endocrinology, Metabolism, and Molecular Medicine (I.S.-H;M.B; RS), Charles R. Drew University, Los Angeles, USA
                     type:PostalAddress
                  type:Organization
                  name:David Geffen School of Medicine at UCLA and Los Angeles Biomedical Research Institute
                  address:
                     name:Division of Endocrinology (A.P.S.H.), Harbor-UCLA Medical Center, David Geffen School of Medicine at UCLA and Los Angeles Biomedical Research Institute, Torrance, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Apoptosis
      issn:
         1573-675X
         1360-8185
      volumeNumber:12
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Charles R. Drew University
      address:
         name:Division of Endocrinology, Metabolism, and Molecular Medicine (I.S.-H;M.B; RS), Charles R. Drew University, Los Angeles, USA
         type:PostalAddress
      name:David Geffen School of Medicine at UCLA and Los Angeles Biomedical Research Institute
      address:
         name:Division of Endocrinology (A.P.S.H.), Harbor-UCLA Medical Center, David Geffen School of Medicine at UCLA and Los Angeles Biomedical Research Institute, Torrance, USA
         type:PostalAddress
      name:Charles R. Drew University
      address:
         name:Division of Endocrinology, Metabolism, and Molecular Medicine (I.S.-H;M.B; RS), Charles R. Drew University, Los Angeles, USA
         type:PostalAddress
      name:David Geffen School of Medicine at UCLA and Los Angeles Biomedical Research Institute
      address:
         name:Division of Endocrinology (A.P.S.H.), Harbor-UCLA Medical Center, David Geffen School of Medicine at UCLA and Los Angeles Biomedical Research Institute, Torrance, USA
         type:PostalAddress
      name:Charles R. Drew University
      address:
         name:Division of Endocrinology, Metabolism, and Molecular Medicine (I.S.-H;M.B; RS), Charles R. Drew University, Los Angeles, USA
         type:PostalAddress
      name:David Geffen School of Medicine at UCLA and Los Angeles Biomedical Research Institute
      address:
         name:Division of Endocrinology (A.P.S.H.), Harbor-UCLA Medical Center, David Geffen School of Medicine at UCLA and Los Angeles Biomedical Research Institute, Torrance, USA
         type:PostalAddress
      name:Charles R. Drew University
      address:
         name:Division of Endocrinology, Metabolism, and Molecular Medicine (I.S.-H;M.B; RS), Charles R. Drew University, Los Angeles, USA
         type:PostalAddress
      name:David Geffen School of Medicine at UCLA and Los Angeles Biomedical Research Institute
      address:
         name:Division of Endocrinology (A.P.S.H.), Harbor-UCLA Medical Center, David Geffen School of Medicine at UCLA and Los Angeles Biomedical Research Institute, Torrance, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Indrani Sinha-Hikim
      affiliation:
            name:Charles R. Drew University
            address:
               name:Division of Endocrinology, Metabolism, and Molecular Medicine (I.S.-H;M.B; RS), Charles R. Drew University, Los Angeles, USA
               type:PostalAddress
            type:Organization
            name:David Geffen School of Medicine at UCLA and Los Angeles Biomedical Research Institute
            address:
               name:Division of Endocrinology (A.P.S.H.), Harbor-UCLA Medical Center, David Geffen School of Medicine at UCLA and Los Angeles Biomedical Research Institute, Torrance, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Mellisa Braga
      affiliation:
            name:Charles R. Drew University
            address:
               name:Division of Endocrinology, Metabolism, and Molecular Medicine (I.S.-H;M.B; RS), Charles R. Drew University, Los Angeles, USA
               type:PostalAddress
            type:Organization
            name:David Geffen School of Medicine at UCLA and Los Angeles Biomedical Research Institute
            address:
               name:Division of Endocrinology (A.P.S.H.), Harbor-UCLA Medical Center, David Geffen School of Medicine at UCLA and Los Angeles Biomedical Research Institute, Torrance, USA
               type:PostalAddress
            type:Organization
      name:Ruoqing Shen
      affiliation:
            name:Charles R. Drew University
            address:
               name:Division of Endocrinology, Metabolism, and Molecular Medicine (I.S.-H;M.B; RS), Charles R. Drew University, Los Angeles, USA
               type:PostalAddress
            type:Organization
            name:David Geffen School of Medicine at UCLA and Los Angeles Biomedical Research Institute
            address:
               name:Division of Endocrinology (A.P.S.H.), Harbor-UCLA Medical Center, David Geffen School of Medicine at UCLA and Los Angeles Biomedical Research Institute, Torrance, USA
               type:PostalAddress
            type:Organization
      name:Amiya P. Sinha Hikim
      affiliation:
            name:Charles R. Drew University
            address:
               name:Division of Endocrinology, Metabolism, and Molecular Medicine (I.S.-H;M.B; RS), Charles R. Drew University, Los Angeles, USA
               type:PostalAddress
            type:Organization
            name:David Geffen School of Medicine at UCLA and Los Angeles Biomedical Research Institute
            address:
               name:Division of Endocrinology (A.P.S.H.), Harbor-UCLA Medical Center, David Geffen School of Medicine at UCLA and Los Angeles Biomedical Research Institute, Torrance, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Division of Endocrinology, Metabolism, and Molecular Medicine (I.S.-H;M.B; RS), Charles R. Drew University, Los Angeles, USA
      name:Division of Endocrinology (A.P.S.H.), Harbor-UCLA Medical Center, David Geffen School of Medicine at UCLA and Los Angeles Biomedical Research Institute, Torrance, USA
      name:Division of Endocrinology, Metabolism, and Molecular Medicine (I.S.-H;M.B; RS), Charles R. Drew University, Los Angeles, USA
      name:Division of Endocrinology (A.P.S.H.), Harbor-UCLA Medical Center, David Geffen School of Medicine at UCLA and Los Angeles Biomedical Research Institute, Torrance, USA
      name:Division of Endocrinology, Metabolism, and Molecular Medicine (I.S.-H;M.B; RS), Charles R. Drew University, Los Angeles, USA
      name:Division of Endocrinology (A.P.S.H.), Harbor-UCLA Medical Center, David Geffen School of Medicine at UCLA and Los Angeles Biomedical Research Institute, Torrance, USA
      name:Division of Endocrinology, Metabolism, and Molecular Medicine (I.S.-H;M.B; RS), Charles R. Drew University, Los Angeles, USA
      name:Division of Endocrinology (A.P.S.H.), Harbor-UCLA Medical Center, David Geffen School of Medicine at UCLA and Los Angeles Biomedical Research Institute, Torrance, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(184)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Clipboard.js
  • Prism.js

CDN Services {📦}

  • Crossref

4.23s.